Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial

Fig. 1

Dispersion of HBV DNA before and after treatment for each group. Data were represented as mean ± standard deviation (SD) for patients in Peg-IFNα-2a group, Peg-IFNα-2a + ETV group, and Peg-IFNα-2a + ADV group at baseline (0 wks), 4 wks, 12 wks, 24 wks, 36 wks, 48 wks of therapy, and 48 wks follow-up. Abbreviations: wks, weeks; ETV, Entecavir, 0.5 mg; ADV, Adefovir 10 mg. *P < 0.0167, indicates a significant difference compared to the Peg-IFNα-2a group. There was no significant difference between the Peg-IFNα-2a + ETV and Peg-IFNα-2a + ADV groups

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us